biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > 2-million-dollar fee

<< Previous

Bullboard Posts

Next >>

Post by emmitfitzhumeon Jan 19, 2023 7:32pm

221 Views

Post# 35234552

2-million-dollar fee

Bioasis market cap as of today is 2.52 million USD. Ladenburg Thalman will receive 2 million USD for their fee in brokering this deal.

Let that sink in.

Bioasis the company, its XB3 technology, all its intellectual property, over a decade of work, and all the preclinical research and development is essentially being valued on par with a fee for concocting this ridiculous deal.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market